TABLE 2.
Study Results
| Matched Controls n = 279 | Clinical Messaging n = 279 | Delta | P Value | |
|---|---|---|---|---|
| All therapies | ||||
| MPR | 66.3 | 73.9 | 7.6 | 0.01 |
| Optimally adherent, % (n) | 43.7 (122) | 53.4 (149) | 9.7% | 0.02 |
| Length of therapy, days | 242.9 | 274.9 | 32.0 | 0.01 |
| First fill drop-off, % (n) | 10.0 (28) | 4.7 (13) | -5.4% | 0.02 |
| Average gap days | 7.8 | 8.0 | 0.2 | 0.91 |
| First-line therapies only (imatinib, dasatinib) | ||||
| MPR | 67.6 | 75.5 | 7.8 | 0.01 |
| Optimally adherent, % (n) | 45.4 (126) | 54.6 (152) | 9.2% | 0.04 |
| Average length of therapy, days | 245.3 | 279.5 | 34.2 | 0.01 |
| First fill drop-off, % (n) | 9.7 (27) | 3.8 (11) | −5.9% | 0.01 |
| Average gap days | 7.5 | 7.8 | 0.3 | 0.85 |
| Imatinib MPR (n = 212) | 69.4 | 73.9 | 4.5% | 0.28 |
| Dasatinib MPR (n = 212) | 65.5 | 76.0 | 10.5% | 0.01 |
| Nilotinib MPR (n = 70) | 60.5 | 65.9 | 5.4% | 0.53 |
| Bosutinib MPR (n = 12) | 46.9 | 60.4 | 13.5% | 0.53 |
MPR = medication possession ratio.